Results 131 to 140 of about 18,455 (220)

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors. [PDF]

Eur J Nucl Med Mol Imaging
di Santo G, Santo G, Wirth L, Kronthaler A, Gastl G, Djanani A, Virgolini IJ.   +6 more
europepmc   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source

Aspects of receptor scintigraphy with neuropeptides [PDF]

, 1995
Breeman, W.A.P. (Wouter)
core  

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]

J Neuroendocrinol
Santo G, di Santo G, Cicone F, Virgolini I.   +3 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

Mol Imaging Biol
Kunte SC, Wenter VU, Holzgreve A, Sheikh GT, Widjaja L, Gildehaus FJ, Lindner S, Schirrmacher R, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +11 more
europepmc   +1 more source

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. [PDF]

Eur J Nucl Med Mol Imaging
Hasenauer N, Müller M, Hänscheid H, Serfling SE, Michalski K, Heinrich M, Polat B, Buck AK, Werner RA, Hartrampf PE.   +9 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy in Patients with Advanced, Recurrent or Progressive Meningioma: An Updated Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Muoio B, Iacovitti CM, Bosetti DG, Sansovini M, Cuzzocrea M, Paone G, Treglia G.   +6 more
europepmc   +1 more source

AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Laudicella R, Faggiano A, Pirro V, Durmo R, Salsi P, Modica R, Urso L, Grana CM, Sances D, Rinzivillo M, Albertelli M, Spada F, Partelli S, Ferraù F, Fazio N, Tafuto S, Maccauro M, Bartolomei M, Panzuto F, De Rimini ML, Lastoria S, Filice A.   +21 more
europepmc   +1 more source